Effects of Surgical Excision on Survival of Patients with Stage IV Breast Cancer

• Published in: The Journal of surgical research 2010-06, Vol.161 (1), p.83-88
• Main Authors: Leung, Anna M., M.D, Vu, Huan N., M.D, Nguyen, Kim-Anh, M.D, Thacker, Leroy R., Ph.D, Bear, Harry D., M.D., Ph.D
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal - therapeutic use; Biological and medical sciences; Bone Neoplasms - mortality; Bone Neoplasms - secondary; Bone Neoplasms - therapy; Breast - surgery; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Female; General aspects; Gynecology. Andrology. Obstetrics; Humans; Kaplan-Meier Estimate; Linear Models; Mammary gland diseases; Medical sciences; Middle Aged; Neoplasm Metastasis; Radiotherapy, Adjuvant; Retrospective Studies; Surgery; Tumors; Virginia - epidemiology
• ISSN: 0022-4804; 1095-8673
• DOI: 10.1016/j.jss.2008.12.030

Background Non-palliative resection of the primary tumor in stage IV breast cancer is controversial. Our aim was to determine whether surgery improves survival in stage IV patients. Methods We reviewed records of all stage IV breast cancer patients (1990–2000) at our institution. Data collection included demographics, metastasis sites, treatment, and survival. Survival was compared between metastasis type, hormonal therapy versus no hormonal therapy, chemotherapy versus no chemotherapy, radiation versus no radiation, and surgery versus no surgery. To ascertain local therapy effects while accounting for chemotherapy, we analyzed survival among chemotherapy alone versus chemotherapy with radiation versus chemotherapy with surgery. We also performed multivariate analysis by multiple linear regression. Results Of 157 patients, 58 (37%) had bone-only metastases, 99 (63%) had visceral metastases. Both groups had a 17-mo median survival. Eighty (51%) received hormonal therapy while 77 (49%) did not. Both groups had a 15-mo median survival. Eighty-four (54%) received chemotherapy with a 25-mo median survival versus 8 mo for 73 (46%) not receiving chemotherapy, Wilcoxon ( P < 0.0001), and log-rank ( P = 0.02). Fifty-eight (37%) received radiation and 99 (63%) did not, with both groups having a 17-mo median survival. Fifty-two (33%) with surgery to the breast primary had a 25-mo median survial, while 105 (67%) without surgery had a 13-mo median survival, Wilcoxon ( P = 0.004) and log-rank ( P = 0.06). Among patients receiving chemotherapy, 37 with chemotherapy alone had a 21-mo median survival versus 40 mo for the 14 with chemotherapy and radiation and 22 mo for the 33 with chemotherapy and surgery. These differences were not significant by Wilcoxon ( P = 0.41) or log-rank ( P = 0.36). Multivariate analysis determined chemotherapy as the only factor associated with improved survival ( P = 0.02). Conclusion Our data, when standardized for chemotherapy, suggests loco-regional therapy does not improve survival.